The most cited evidence on GLP-1 rebound comes from the STEP 1 trial extension. After 68 weeks of treatment with semaglutide 2.4 mg, participants had lost an average of 14.9% of body weight. When a subset of participants discontinued the medication (Wilding JPH et al.